Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (20172)	3/30/1999 1:50:00 AM
From: VLAD	Respond to of 23519

martin, Once we get global marketing expansion of MUSE Vivus will be able to generate substantial earnings. MUSE product sale income alone will easily bring Vivus over $1.00/share annual earnings income. I think we will see this level of income starting with the European launches and Vivus will build earnings momentum as a domestic partner is signed and countries such as China and Japan get on line. I think that the female SD product will eventually generate greater earnings income than MUSE and Alibra combined. The question is exactly how quickly can Vivus get such a product through clinical trials and on the market. I believe that information regarding this new product will give Vivus share price upward momentum as developments continue to unfold and more information is released by Vivus. I wonder if the development of such a product will be primarily Vivus' responsibility or whether it will be in the hands of a larger player that will eventually market the product. IMHO Astra/Zeneca will be our eventual domestic marketing partner for MUSE and then Alibra. I also feel that they will give Vivus all the necessary backing (financial and otherwise) to get the female SD product on the market ASAP. I am also very curious about the new product technology recently aquired by Vivus. I expect that we will all know about this no later than by April's conference call.